Quantcast

Latest Dirucotide Stories

2009-07-30 16:00:00

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences...

2009-07-27 16:00:00

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide...

2009-05-28 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, May 28 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting & Symposium. TITLE: "Dirucotide: A Potential Therapy for Multiple Sclerosis" WHEN: Thursday June 4th at 2:00 pm (Eastern Time) WHERE:...

2009-05-14 07:00:00

- "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" - Toronto Stock Exchange Symbol: MS EDMONTON, May 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Richard Brown, Vice President, Commercial Development, BioMS Medical and Mr. Jack Tupman, Senior Director, Corporate Business Development, Eli Lilly and Company, will take part in a Technology Transfer/Licensing session at the BIO...

2009-05-11 16:30:00

Toronto Stock Exchange Symbol: MS EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009. "We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese,...

2009-04-29 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled "Leveraging on energy wealth: the development of a world class technology sector" as part of the Alberta Economic Forum in Geneva in Switzerland. WHEN: Monday May 4th at 10:05am (Local time) WHERE: Grand Hotel...

2009-04-24 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, will present at BioFinance 2009 in Toronto. WHEN: Wednesday April 29th at 11:00am (Eastern Time) WHERE: Toronto Marriott Eaton Centre Hotel (Trinity V room) 525 Bay Street Toronto, ON About BioFinance 2009...

2009-04-21 11:05:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was the final scheduled...

2009-04-14 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was the fourth of several regularly...

2009-03-17 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008. "Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related